Infections and hypogammaglobulinemia in myasthenia gravis patients receiving low-dose rituximab: a real-world cohort study. (PubMed, Front Immunol) - Sep 13, 2026 - "We investigated the incidence of infections and hypogammaglobulinemia (HGG) in patients with myasthenia gravis (MG) receiving long-term low-dose rituximab (RTX) maintenance therapy and identified related risk factors. In MG patients receiving long-term low-dose RTX maintenance, the overall infection incidence is relatively low, with LRTIs being the most frequent. HGG is a major independent risk factor for infections and severe LRTIs, while higher baseline prednisone doses were associated with severe LRTIs."
Journal • Real-world evidence • Retrospective data • CNS Disorders • Immunology • Infectious Disease • Myasthenia Gravis • Respiratory Diseases
|
|
Chao Sun; Danni Liu; Qingqing Wang; Rongjing Guo; Sijia Hao; Ting Chang; Ting Gao; Xiangqi Cao; Xiaoxi Huang; Yifan Zhang; Yonglan Tang; Yu Liu; Zhe Ruan; Zhuyi Li
|